Skip to main content
Equibles
RARE logo

RARE · Ultragenyx Pharmaceutical Inc.

Track RARE — free

Use RARE with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

Claude ChatGPT Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$15.30 +0.45 (+3.03%) At close · Sep 4
Russell 2000 member Rebalance outlook locked
Market Cap
$1.51B
Shares
98.59M

RARE metrics

61 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$15.30
Market cap
$1.51B

Price action

19 metrics
Price change (1W)
-40.3%
Price change (30D)
-42.9%
Price change (3M)
-30.2%
Price change (6M)
-28.0%
Price change (YTD)
-33.5%
Price change (1Y)
-51.1%
Trailing year
Price change (5Y)
-85.1%
52-week high
$36.54
52-week low
$14.85
Change from 52-week high
-58.1%
Change from 52-week low
+3.0%
Annualized volatility
80.4%
Beta
1.2
RSI (14D)
21.1
Price vs SMA 50
-44.8%
Price vs SMA 200
-41.1%
Avg volume (3M)
2.97M
Relative volume
3.9
Average dollar volume
$75.75M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
98.59M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
2.1×
reciprocal yield 47.5%
P / book
—
FCF yield
-32.4%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-38.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-04

Profitability

9 metrics
Gross margin
—
Operating margin
-73.6%
Trailing 12 months
Net margin
-81.7%
Gross profit (TTM)
—
Operating profit (TTM)
−$528.00M
Net income (TTM)
−$586.00M
Trailing 12 months
Diluted EPS (TTM)
$-5.83
FCF margin
-68.2%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-19.87

Growth

11 metrics
Revenue growth YoY
+28.1%
Year over year
Net income growth YoY
—
Revenue (TTM)
$717.00M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+3.5%
Year over year · more shares
Revenue CAGR (3Y)
+22.8%
Revenue CAGR (5Y)
+19.9%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-46.4%
Debt / equity
—
Current ratio
1.7
EBITDA (TTM)
−$495.00M
Free cash flow (TTM)
−$489.00M
Quick ratio
1.6
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$125.00M
Total assets
$1.26B
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$485.00M
Capital expenditures (TTM)
$4.00M
R&D (TTM)
$773.00M
SG&A (TTM)
$351.00M
Stock compensation (TTM)
$75.08M
R&D / revenue
107.8%
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
317
13F filer change QoQ
+19
Institutional ownership
112.0%

Short interest

3 metrics
Short interest
16.1%
Latest settlement · 7.8 days to cover
Days to cover
7.8d
Short-squeeze score
58 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$416,870
Insider-sentiment score
56 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1515673 CUSIP 90400D108 13F (30d) 220 filings 219 filers Visit website Investor relations